Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 10/20 | 0.33 |
| ▸ | SCN2B | O60939 | 1/20 | 0.32 |
| ▸ | SCN1A | P35498 | 1/20 | 0.32 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19686033 | 0.92 | PGR (0.32) | MEN1KMT2AMAPK8SCN2BSCN1A | |
| SCHEMBL19685873 | 0.91 | SCN2B (0.36) | MEN1KMT2ASCN2BSCN1ASCN1B | |
| SCHEMBL19685823 | 0.90 | MAPK8 (0.33) | MAPK8SCN2BSCN1ASCN1BSCN5A | |
| SCHEMBL19685922 | 0.89 | MAPK8 (0.32) | MAPK8SCN2BSCN1ASCN1BSCN5A | |
| SCHEMBL19685925 | 0.89 | MAPK8 (0.32) | MAPK8SCN2BSCN1ASCN1BSCN5A | |
| SCHEMBL19685736 | 0.87 | MEN1 (0.35) | MEN1KMT2APGRALDH1A1 | |
| SCHEMBL19685878 | 0.85 | SCN2B (0.37) | MEN1KMT2AMAPK8SCN2BSCN1A | |
| SCHEMBL19686037 | 0.83 | ESR1 (0.38) | MEN1KMT2APGRALDH1A1 | |
| SCHEMBL19685994 | 0.83 | ESR1 (0.36) | MEN1KMT2ASCN2BSCN1ASCN1B | |
| SCHEMBL19686169 | 0.83 | SCN2B (0.34) | MEN1KMT2ASCN2BSCN1ASCN1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10714693-B2 | Polycyclic compound and organic electroluminescence device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-07-14 | — | — | US | disclosed |
| US-20170352817-A1 | POLYCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THE SAME | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10714693-B2 | Polycyclic compound and organic electroluminescence device including the same | CYC1, CCNA1, CYCS | MEN1 644/4885KMT2A 1444/4885MAPK8 1533/4885 |
| US-20170352817-A1 | POLYCYCLIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THE SAME | CYC1, CCNA1, CYCS | MEN1 644/4885KMT2A 1444/4885MAPK8 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.